Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating lease liability | (41) | (42) |
| Net cash used in operating activities | (20,208) | (22,678) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (437) | (30) |
| Purchases of marketable securities | (154,160) | (58,894) |
| Maturities of marketable securities | 57,500 | 57,150 |
| Call redemptions of marketable securities | — | 5,000 |
| Net cash (used in) provided by investing activities | (97,097) | 3,226 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s capex?
- MBX Biosciences, Inc. (MBX) reported capex of $437K in Q1 2026.
- How has MBX Biosciences, Inc.'s capex changed year-over-year?
- MBX Biosciences, Inc.'s capex increased by 1356.7% year-over-year, from $30K to $437K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about MBX Biosciences, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude